Artificial Pancreas Devices Systems Market By Device Type (Threshold Suspend Device Systems, Control-To-Range (CTR) Systems, Control-To-Target (CTT) Systems) , By End User (Hospitals, Clinics, Homecare) : Global Opportunity Analysis and Industry Forecast, 2024-2033
The artificial pancreas devices systems market was valued at $0.4 billion in 2023, and is projected to reach $0.8 billion by 2033, growing at a CAGR of 8.8% from 2024 to 2033.
Artificial pancreas device is a medical device that mimics the glucose-regulating function of a healthy pancreas, aiming to maintain optimal blood sugar levels. This medical technology is primarily designed to monitor and regulate blood glucose levels in individuals suffering from diabetes, particularly those with type 1 diabetes. These devices aim to restore lost functions, enhance human capabilities, and improve overall quality of life.
The growth of the artificial pancreas devices systems market is majorly driven by alarming increase in global prevalence of diabetes, particularly type 1 diabetes and rise in awareness among patients and healthcare providers about the benefits of artificial pancreas systems. According to the 2021 key findings of IDF Diabetes Atlas 10th edition, approximately 537 million adults are suffering diabetes. This number is estimated to reach 643 million by 2030 and 783 million by 2045. Around 6.7 million deaths were reported due to diabetes in 2021. Moreover, increase in healthcare expenditure, particularly in emerging economies, allows more patients to access advanced diabetes management technologies. As per the same source, diabetes was responsible for at least $966 billion dollars in health expenditure in 2021. Furthermore, the integration of artificial pancreas devices systems with digital health platforms and smartphone applications enhances patient engagement and allows for better remote monitoring and management, which acts as the key driving force of the market. However, high cost associated with the artificial pancreas devices systems restrains the growth of the market. Moreover, lack of appropriate health facilities to meet population needs in most countries and limited access act as the key deterrent factors of the market. On the contrary, continuous improvements in sensor technology, insulin delivery systems, and control algorithms enhance the performance and reliability of artificial pancreas systems, which are expected to offer remunerative opportunities for the expansion of the global market during the forecast period. In addition, increase in initiatives aimed at improving diabetes care and management are providing incentives for the adoption of artificial pancreas systems. For instance, the World Health Organization launched an initiative in April 2021, WHO Global Diabetes Compact. The initiative aims to reduce the risk of diabetes and ensure that diabetic individuals have access to affordable and quality treatment and care.
The artificial pancreas devices systems industry is segmented into device type, end user, and region. By device type, the market is divided into threshold suspend device systems, control-to-range (CTR) systems, and control-to-target (CTT) systems. On the basis of end user, it is divided into hospitals, clinics, homecare. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key FindingsBy device type, the threshold suspend device systems segment dominated the market, in terms of share, in 2023.
Depending on end user, the homecare segment captured the largest share in 2023.
Region wise, North America holds a dominant position in the market in 2023.
Competition AnalysisCompetitive analysis and profiles of the major players in the global artificial pancreas devices systems market include Medtronic plc, Bigfoot Biomedical, Inc., Johnson & Johnson, Tandem Diabetes Care, Inc., Pancreum, Inc, TypeZero Technologies, LLC, Beta Bionics, Inc, Insulate Corporation, Diabeloop, and Inreda Diabetic. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.
Key Market SegmentsBy Device TypeThreshold Suspend Device Systems
Control-To-Range (CTR) Systems
Control-To-Target (CTT) Systems
By End UserHospitals
Clinics
Homecare
By RegionNorth America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Medtronic plc
Bigfoot Biomedical, Inc.
Johnson & Johnson
Tandem Diabetes Care, Inc.
Pancreum, Inc
TypeZero Technologies, LLC
Beta Bionics, Inc
Insulate Corporation
Diabeloop
Inreda Diabetic